The label for Glofitamab, marketed as Columvi, has been updated by the FDA to include a prominent Boxed Warning, effective 2026-06-03. This significant revision highlights the risk of Cytokine Release Syndrome (CRS), emphasizing that serious or even fatal reactions can occur in patients receiving the drug. The warning also outlines crucial mitigation strategies, including mandatory premedication before each dose and the implementation of a step-up dosing schedule for treatment initiation.
What this means
The addition of a Boxed Warning to the Columvi (glofitamab) label represents a critical communication from the FDA to healthcare professionals regarding a significant safety concern. This type of warning, often referred to as a 'black box warning,' is the strongest safety alert the FDA requires, indicating that the drug carries a serious risk of adverse effects that may lead to severe injury or death. In the case of Columvi, the warning specifically addresses Cytokine Release Syndrome (CRS). The label explicitly states that CRS, including reactions that have been serious or fatal, can occur in patients undergoing treatment with Columvi. This necessitates careful patient selection, monitoring, and proactive management. To minimize the risk and severity of CRS, the updated prescribing information mandates specific protocols. Firstly, patients must receive premedication before each dose of Columvi. This proactive measure aims to attenuate the inflammatory response associated with CRS. Secondly, the initiation of Columvi treatment must adhere to a step-up dosing schedule. This gradual approach allows the body to adapt to the drug, potentially reducing the sudden and severe onset of CRS. Healthcare providers are therefore advised to strictly follow these updated guidelines, ensuring appropriate patient education, vigilant monitoring for signs and symptoms of CRS, and prompt intervention if CRS develops, thereby enhancing the overall safety profile of glofitamab therapy.
Source
The information regarding this label revision for Columvi (glofitamab) was issued by the FDA. The revised prescribing information, which includes the Boxed Warning, became effective on 2026-06-03. The official document can be accessed via dailymed.nlm.nih.gov, a service of the National Library of Medicine providing information on marketed drugs.